Publication Listing for the MeSH term single-chain fv. Found 14 abstracts

Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded

Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biotherapy and Radiopharmaceuticals. 2005 Jun;20(3):239-48.

Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol. 2005 May;23(5):556-7.

Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy. Drug Development Research. 2004 Mar;61(3):172-87.

Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering Design & Selection. 2004 May;17(5):455-62.

Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15;60(22):6434-40.

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep;301(5):1149-61.

Adams GP. Improving the tumor specificity and retention of antibody-based molecules. In Vivo. 1998 Jan;12(1):11-21.

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May;77(9):1405-12.

Bookman MA. Biological therapy of ovarian cancer: Current directions. Semin Oncol. 1998 Jun;25(3):381-96.

Amoroso AR, Clark JI, Litwin S, HsiehMa S, Shi T, Alpaugh RK, Adams GP, Wolf EJ, Ring DB, Weiner LM. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Cancer Res. 1996 Jan;56(1):113-20.

Adams GP, McCartney JE, Wolf EJ, Oppermann H, Tai MS, Eisenberg J, Giantonio B, Schultz J, Bookman MA, Laminet AA, Apell G, Stafford WF, Liu S, Huston JS, Houston LL, Weiner LM. Preclinical Studies and Optimization of Specific Tumor Delivery for 741f8 Sfv, an Anti-C-Erbb-2 Single-Chain Species. International Journal of Pharmacognosy. 1995 Jan;33:75-91.

McCartney JE, Tai MS, Hudziak RM, Adams GP, Weiner LM, Jin D, Stafford WF, Liu S, Bookman MA, Laminet AA, Fand I, Houston LL, Oppermann H, Huston JS. Engineering Disulfide-Linked Single-Chain Fv Dimers (Sfv')(2) with Improved Solution and Targeting Properties - Antidigoxin- 26-10 (Sfv')(2) and Anti-C-Erbb-2 741f8 (Sfv')(2) Made by Protein-Folding and Bonded through C-Terminal Cysteinyl Peptides. Protein Eng. 1995 Mar;8(3):301-14.

Bookman MA. Biologic Therapy in the Management of Refractory Ovarian-Cancer. Gynecol Oncol. 1993 Oct;51(1):113-26.

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

single-chain fv escherichia-coli monoclonal-antibody b-cell lymphoma phase-i trial protein fragments tumor targeting immunoglobulin forms nude-mice antibodies biodistribution radiolabeling colony-stimulating factor mice cancer recombinant gamma-interferon affinity breast-cancer monoclonal-antibodies expression binding-site factor receptor expression tumor-necrosis-factor her-2 receptor human transferrin enzyme fusion human carcinoma antibody fragment optimized delivery phage-display technology signal-transduction bispecific antibodies colorectal-cancer vascular leak syndrome chimeric antibodies binding sites tyrosine kinases t- c-erb-2 extracellular domain ovarian-cancer single chain Fv receptor mediated endocytosis cell-binding nonspecific animal toxicity neu oncoprotein pichia-pastoris activated killer-cells library model phage antibody library fc-gamma-riii immuno-targeting hybrid hybridomas recovery lymphocytes phase-i nude- positron-emission-tomography HER2 Diabody-Pichia-E coli-PET imaging activated ErbB2 surface display internalization phage display fusion protein transformation bivalent imaging diabody epidermal growth-factor tumor penetration tissue staphylococcal protein-a in-vitro bacterial receptor domain HER2 affibody-ligand-phage display-selection single chain monoclonal-antibody co17-1a evolution early prediction tumors binding-proteins xenografts selection glycosylation single-chain Fv killer-cells idiotype antibodies proteins (sfv')(2) carcinoma cytotoxic lymphocytes-t 1995 oe ys-journal of medicinal chemistry-v38-p816 tumour targeting Fv sfv taq dna-polymerase combinatorial libraries carcinoma ascitic fluid metastatic breast-cancer distribution human lymphocytes-t endothelial growth-factor digoxin pharmacokinetics monoclonal-antibody hmfg2 delivery (sfv')(2) dimers miniantibodies c-erbb-2 immunodeficient mice dna her-2 neu trial human-breast-cancer growth-inhibition human monoclonal-antibodies dose c-erbb-2 oncogene monoclonal antibodies bispecific monoclonal- non-hodgkins-lymphoma cytotoxicity c-ErbB-2 affibody-HER-2-iodine-radionuclide-SKBR-3-tumor avidity cells display library binding-properties binding-site barrier